Sarepta Therapeutics (SRPT) Interest Coverage Ratio (2010 - 2026)
Sarepta Therapeutics (SRPT) posted quarterly Interest Coverage Ratio of 0.35 for Q1 2026, up 214.12% year-over-year from 0.11 in Q1 2025, and up 101.1% quarter-over-quarter from 31.63 in Q4 2025.
Sarepta Therapeutics (SRPT) Interest Coverage Ratio (2010 - 2026) Analysis & Trends
Sarepta Therapeutics' Interest Coverage Ratio history runs 17 years deep, the most recent figure standing at 0.35 for Q1 2026.
- In Q1 2026, Interest Coverage Ratio rose 214.12% year-over-year to 0.35; the TTM figure through Mar 2026 stood at 0.04 (up 66.58% YoY), while the FY2025 annual figure was 0.63, down 223.21% from the prior year.
- Interest Coverage Ratio for Q1 2026 stood at 0.35, up from 31.63 in the prior quarter.
- The five-year high for Interest Coverage Ratio was 51.31 in Q4 2022, with the low at 31.63 in Q4 2025.
- The 5-year median for Interest Coverage Ratio is 0.63 (2023), against an average of 3.36.
- The sharpest annual moves came in 2022 and 2024: Interest Coverage Ratio surged 273.95% in 2022, then plunged 658.81% in 2024.
- Sarepta Therapeutics' Interest Coverage Ratio stood at 51.31 in 2022, then tumbled by 101.24% to 0.63 in 2023, then slumped by 658.81% to 4.82 in 2024, then sank by 556.51% to 31.63 in 2025, then soared by 101.1% to 0.35 in 2026.
- Business Quant data shows SRPT's Interest Coverage Ratio at 0.35 in Q1 2026, 31.63 in Q4 2025, and 0.09 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.84 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 24.64 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -0.19 |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.18 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.01 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.61 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.82 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.08 |
| 10 | Sarepta Therapeutics | 1.91 Bn | 1.12 Bn | 251.87 Mn | -0.62 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -0.62 |
| Mar 31, 2026 | 0.35 |
| Dec 31, 2025 | -31.63 |
| Sep 30, 2025 | -0.09 |
| Jun 30, 2025 | 0.10 |
| Mar 31, 2025 | -0.30 |
| Dec 31, 2024 | -4.82 |
| Sep 30, 2024 | 0.02 |
| Jun 30, 2024 | -0.15 |
| Mar 31, 2024 | 4.86 |
| Dec 31, 2023 | -0.63 |
| Sep 30, 2023 | -3.99 |
| Jun 30, 2023 | -25.56 |
| Mar 31, 2023 | -19.66 |
| Dec 31, 2022 | 51.31 |
| Sep 30, 2022 | -8.91 |
| Jun 30, 2022 | -12.45 |
| Mar 31, 2022 | -5.50 |
| Dec 31, 2021 | -29.50 |
| Sep 30, 2021 | -1.67 |